News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations Limited announces successful preclinical study results of its second-generation nanoparticle formulation of PNKP Compound, showing enhanced inhibitor delivery with minimal toxicity for potential cancer therapy -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph
Onco-Innovations subsidiary, Inka Health, files patent for AI platform SynoGraph, enhancing precision medicine and oncology drug development. SynoGraph leverages AI-driven causal inference for treatment optimization -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces U.S. Listing on the OTCQB Market
Onco-Innovations Limited announces commencement of trading on OTCQB marketplace under symbol 'ONNVF', enhancing visibility for U.S. investors. Company remains listed on the Canadian Securities Exchange under symbol 'ONCO'
